mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
Patricia Ibeas, Blanca Cantos, Mariano ProvencioClinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, SpainAbstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refr...
Guardado en:
Autores principales: | Provencio M., Cantos B, Ibeas P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e113c6da2f18452db564f0ea77074c2e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reduced intensity treatment in early-stage Hodgkin’s lymphoma
por: Armitage JO, et al.
Publicado: (2011) -
MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021) -
ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
por: Sanda Buruiana, et al.
Publicado: (2021) -
Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
por: John R. Krause, et al.
Publicado: (2021) -
MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)